Repligen Corporation (RGEN) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $132.12 (+1.01%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 14, 2026 | Luke Sergott | Barclays | $145.00 | +9.7% |
| Jan 16, 2026 | Dan Leonard | UBS | $200.00 | +51.4% |
| Oct 28, 2025 | Matthew Stanton | Jefferies | $160.00 | +21.1% |
| Oct 2, 2025 | Luke Sergott | Barclays | $160.00 | +21.1% |
| Nov 12, 2024 | Paul Knight | KeyBanc | $220.00 | +66.5% |
| Jul 31, 2024 | Rachel Vatnsdal | J.P. Morgan | $200.00 | +51.4% |
| Jul 31, 2024 | Elizabeth Garcia | UBS | $185.00 | +40.0% |
| Jun 26, 2024 | Justin Bowers | Deutsche Bank | $155.00 | +17.3% |
| Jun 21, 2024 | Daniel Arias | Stifel Nicolaus | $207.00 | +56.7% |
Top Analysts Covering RGEN
RGEN vs Sector & Market
| Metric | RGEN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.08 | 2.24 | 2.40 |
| Analyst Count | 12 | 8 | 19 |
| Target Upside | +23.7% | +11475.0% | +17.1% |
| P/E Ratio | 146.80 | 3.77 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $817M | $827M | $835M | 16 |
| 2027-03-31 | $219M | $222M | $225M | 5 |
| 2027-06-30 | $232M | $235M | $239M | 6 |
| 2027-09-30 | $239M | $243M | $246M | 9 |
| 2027-12-31 | $251M | $255M | $258M | 5 |
| 2028-03-31 | $244M | $247M | $251M | 4 |
| 2028-06-30 | $256M | $260M | $263M | 6 |
| 2028-09-30 | $265M | $269M | $272M | 9 |
| 2028-12-31 | $282M | $286M | $290M | 4 |
| 2029-12-31 | $1.26B | $1.28B | $1.29B | 7 |
| 2030-12-31 | $1.45B | $1.47B | $1.49B | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.95 | $1.97 | $2.00 | 12 |
| 2027-03-31 | $0.53 | $0.53 | $0.54 | 3 |
| 2027-06-30 | $0.61 | $0.62 | $0.63 | 3 |
| 2027-09-30 | $0.65 | $0.66 | $0.67 | 4 |
| 2027-12-31 | $0.72 | $0.73 | $0.74 | 3 |
| 2028-03-31 | $0.74 | $0.75 | $0.76 | 4 |
| 2028-06-30 | $0.77 | $0.78 | $0.80 | 4 |
| 2028-09-30 | $0.81 | $0.82 | $0.84 | 6 |
| 2028-12-31 | $0.83 | $0.85 | $0.86 | 4 |
| 2029-12-31 | $4.36 | $4.43 | $4.50 | 1 |
| 2030-12-31 | $5.58 | $5.68 | $5.77 | 1 |
Frequently Asked Questions
What is the analyst consensus for RGEN?
The consensus among 12 analysts covering Repligen Corporation (RGEN) is Buy with an average price target of $183.00.
What is the highest price target for RGEN?
The highest price target for RGEN is $220.00, set by Paul Knight at KeyBanc on 2024-11-12.
What is the lowest price target for RGEN?
The lowest price target for RGEN is $145.00, set by Luke Sergott at Barclays on 2026-04-14.
How many analysts cover RGEN?
12 analysts have issued ratings for Repligen Corporation in the past 12 months.
Is RGEN a buy or sell right now?
Based on 12 analyst ratings, RGEN has a consensus rating of Buy (2.08/5) with a +23.7% upside to the consensus target of $183.00.
What are the earnings estimates for RGEN?
Analysts estimate RGEN will report EPS of $1.97 for the period ending 2026-12-31, with revenue estimated at $827M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.